These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37268829)

  • 41. Lower Annual Rate of Progression of Short-Segment vs Long-Segment Barrett's Esophagus to Esophageal Adenocarcinoma.
    Hamade N; Vennelaganti S; Parasa S; Vennalaganti P; Gaddam S; Spaander MCW; van Olphen SH; Thota PN; Kennedy KF; Bruno MJ; Vargo JJ; Mathur S; Cash BD; Sampliner R; Gupta N; Falk GW; Bansal A; Young PE; Lieberman DA; Sharma P
    Clin Gastroenterol Hepatol; 2019 Apr; 17(5):864-868. PubMed ID: 30012433
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical pathways and outcomes of patients with Barrett's esophagus in tertiary care settings: a prospective longitudinal cohort study in Australia, 2008-2016.
    Na R; Miura K; O'Brien S; Eslick GD; Kendall BJ; Hourigan LF; Bourke M; Cox MR; Farrokhzadi L; Levert-Mignon AJ; Barbour AP; Clemons NJ; Duong CP; Lord RV; Phillips WA; Watson DI; Whiteman DC
    Dis Esophagus; 2021 Aug; 34(8):. PubMed ID: 33306781
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The diagnosis and management of Barrett's esophagus.
    DeMeester SR; DeMeester TR
    Adv Surg; 1999; 33():29-68. PubMed ID: 10572561
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Endoscopic therapy of esophageal premalignancy and early malignancy.
    Nealis TB; Washington K; Keswani RN
    J Natl Compr Canc Netw; 2011 Aug; 9(8):890-9. PubMed ID: 21900219
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dysplasia in Random Biopsies from Barrett's Surveillance Is an Important Marker for More Severe Pathology.
    Noordzij IC; Van Loon van de Ende MCM; Curvers WL; van Lijnschoten G; Huysentruyt CJ; Schoon EJ
    Dig Dis Sci; 2021 Jun; 66(6):1957-1964. PubMed ID: 32661766
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study.
    Bhat S; Coleman HG; Yousef F; Johnston BT; McManus DT; Gavin AT; Murray LJ
    J Natl Cancer Inst; 2011 Jul; 103(13):1049-57. PubMed ID: 21680910
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Low Risk of Progression of Barrett's Esophagus to Neoplasia in Women.
    Allen JE; Desai M; Roumans CAM; Vennalaganti S; Vennalaganti P; Bansal A; Falk G; Lieberman D; Sampliner R; Thota P; Vargo J; Gupta N; Moawad F; Bruno M; Kennedy KF; Gaddam S; Young P; Mathur S; Cash B; Spaander M; Sharma P
    J Clin Gastroenterol; 2021 Apr; 55(4):321-326. PubMed ID: 32379085
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Persistent intestinal metaplasia after endoscopic eradication therapy of neoplastic Barrett's esophagus increases the risk of dysplasia recurrence: meta-analysis.
    Sawas T; Alsawas M; Bazerbachi F; Iyer PG; Wang KK; Murad MH; Katzka DA
    Gastrointest Endosc; 2019 May; 89(5):913-925.e6. PubMed ID: 30529044
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus.
    Kastelein F; Spaander MC; Biermann K; Steyerberg EW; Kuipers EJ; Bruno MJ;
    Gastroenterology; 2011 Dec; 141(6):2000-8; quiz e13-4. PubMed ID: 21878200
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Significantly lower annual rates of neoplastic progression in short- compared to long-segment non-dysplastic Barrett's esophagus: a systematic review and meta-analysis.
    Chandrasekar VT; Hamade N; Desai M; Rai T; Gorrepati VS; Jegadeesan R; Sathyamurthy A; Sharma P
    Endoscopy; 2019 Jul; 51(7):665-672. PubMed ID: 30939618
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus.
    Kastelein F; Biermann K; Steyerberg EW; Verheij J; Kalisvaart M; Looijenga LH; Stoop HA; Walter L; Kuipers EJ; Spaander MC; Bruno MJ;
    Gut; 2013 Dec; 62(12):1676-83. PubMed ID: 23256952
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort.
    Reid BJ; Blount PL; Rubin CE; Levine DS; Haggitt RC; Rabinovitch PS
    Gastroenterology; 1992 Apr; 102(4 Pt 1):1212-9. PubMed ID: 1551528
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical prediction model for tumor progression in Barrett's esophagus.
    Holmberg D; Ness-Jensen E; Mattsson F; Lagergren J
    Surg Endosc; 2019 Sep; 33(9):2901-2908. PubMed ID: 30456503
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [The influence of Barrett's esophagus on the clinical signs and postoperative results of GERD].
    Endzinas Z; Mickevicius A; Kiudelis M
    Zentralbl Chir; 2004 Apr; 129(2):99-103. PubMed ID: 15106039
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Incidence of adenocarcinoma among patients with Barrett's esophagus.
    Hvid-Jensen F; Pedersen L; Drewes AM; Sørensen HT; Funch-Jensen P
    N Engl J Med; 2011 Oct; 365(15):1375-83. PubMed ID: 21995385
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression.
    Skacel M; Petras RE; Gramlich TL; Sigel JE; Richter JE; Goldblum JR
    Am J Gastroenterol; 2000 Dec; 95(12):3383-7. PubMed ID: 11151865
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Patient predictors of histopathologic response after photodynamic therapy of Barrett's esophagus with high-grade dysplasia or intramucosal carcinoma.
    Yachimski P; Puricelli WP; Nishioka NS
    Gastrointest Endosc; 2009 Feb; 69(2):205-12. PubMed ID: 18950764
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus.
    Wani S; Falk GW; Post J; Yerian L; Hall M; Wang A; Gupta N; Gaddam S; Singh M; Singh V; Chuang KY; Boolchand V; Gavini H; Kuczynski J; Sud P; Bansal A; Rastogi A; Mathur SC; Young P; Cash B; Goldblum J; Lieberman DA; Sampliner RE; Sharma P
    Gastroenterology; 2011 Oct; 141(4):1179-86, 1186.e1. PubMed ID: 21723218
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Radiofrequency Ablation Is Associated With Decreased Neoplastic Progression in Patients With Barrett's Esophagus and Confirmed Low-Grade Dysplasia.
    Small AJ; Araujo JL; Leggett CL; Mendelson AH; Agarwalla A; Abrams JA; Lightdale CJ; Wang TC; Iyer PG; Wang KK; Rustgi AK; Ginsberg GG; Forde KA; Gimotty PA; Lewis JD; Falk GW; Bewtra M
    Gastroenterology; 2015 Sep; 149(3):567-76.e3; quiz e13-4. PubMed ID: 25917785
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Complete Barrett's eradication endoscopic mucosal resection: an effective treatment modality for high-grade dysplasia and intramucosal carcinoma--an American single-center experience.
    Chennat J; Konda VJ; Ross AS; de Tejada AH; Noffsinger A; Hart J; Lin S; Ferguson MK; Posner MC; Waxman I
    Am J Gastroenterol; 2009 Nov; 104(11):2684-92. PubMed ID: 19690526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.